Internal Reference Number: FOI_9372
Date Request Received: 28/04/2026 00:00:00
Date Request Replied To: 12/05/2026 00:00:00
This response was sent via: By Email
Request Summary: Multiple Myeloma
Request Category: Companies
| Question Number 1: Could you please provide the data for the last three months, i.e., January 2026 to March 2026. Over the past 3 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. | |
| Answer To Question 1: 76 patients | |
| Question Number 2: Of the multiple myeloma patients over the past 6 months, how many were treated with the following: • Belantamab Mafodotin [Blenrep] • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] ± Dexamethasone • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Daratumumab [Darzalex] monotherapy • Elranatamab • Idecabtagene vicleucel [Abecma] • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) • Lenalidomide [Revlimid] + Dexamethasone • Lenalidomide [Revlimid] monotherapy • Panobinostat + Bortezomib + Dexamethasone • Pomalidomide [Imnovid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Talquetamab • Teclistamab [Tecvayli] • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] | |
| Answer To Question 2: • Belantamab Mafodotin [Blenrep] less than 5 • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone less than 5 • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0 • Bortezomib [Velcade] ± Dexamethasone 0 • Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) 0 patients (see other for VCD) • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0 • Carfilzomib [Kyprolis] + Dexamethasone 0 • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) less than 5 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 12 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 7 • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 10 • Daratumumab [Darzalex] monotherapy 0 • Elranatamab 6 • Idecabtagene vicleucel [Abecma] 0 • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 0 • Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) 5 • Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) 8 • Lenalidomide [Revlimid] + Dexamethasone less than 5 • Lenalidomide [Revlimid] monotherapy 29 • Panobinostat + Bortezomib + Dexamethasone less than 5 • Pomalidomide [Imnovid] + Dexamethasone 0 • Selinexor + Bortezomib [Velcade] + Dexamethasone 0 • Selinexor + Dexamethasone 0 • Talquetamab 0 • Teclistamab [Tecvayli] 0 • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] Less than 5 each for VCD (bortezomib/cyclophosphamide/dexamethasone), venetoclax, daratumumab/lenalidomide | |
| Question Number 3: In the last 3 months, how many patients have been initiated* on the following regimens? • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) • Carfilzomib [Kyprolis] + Dexamethasone • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) • Lenalidomide [Revlimid] monotherapy • Lenalidomide [Revlimid] + Dexamethasone • Selinexor + Bortezomib [Velcade] + Dexamethasone • Selinexor + Dexamethasone • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. | |
| Answer To Question 3: • Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone less than 5 • Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone 0 • Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) 0 • Carfilzomib [Kyprolis] + Dexamethasone 0 • Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) 0 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) 0 • Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) 0 • Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) 0 • Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) 0 • Lenalidomide [Revlimid] monotherapy 0 • Lenalidomide [Revlimid] + Dexamethasone 0 • Selinexor + Bortezomib [Velcade] + Dexamethasone 0 • Selinexor + Dexamethasone 0 • Any other systemic anti-cancer therapy for Multiple Myeloma Only [please specify] less than 5 each for elranatamab and IRD *Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) in the 6 months prior to initiation. | |
| Question Number 4: In the last 3 months, how many patients have received the following second-line treatment? • Lenalidomide [Revlimid] + Dexamethasone | |
| Answer To Question 4: • Lenalidomide [Revlimid] + Dexamethasone 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
